 Home > Biochemistry News > Biotechnology News > Denali macromolecule delivery technology that breaks through the blood-brain barrier is expected to advance to phase 2/3 clinical trials

Denali macromolecule delivery technology that breaks through the blood-brain barrier is expected to advance to phase 2/3 clinical trials

 Last Update: 2022-05-01
 Source: Internet
 Author: User

Tags

1 2 micrometer

all natural shampoo

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Denali Therapeutics today announced updated long-term data from an ongoing Phase 1/2 clinical trial of its investigational enzyme replacement therapy DNL310

MPS II is a rare neurodegenerative lysosomal storage disorder caused by mutations in the gene encoding the IDS protease

The blood-brain barrier is critical in maintaining the brain microenvironment and protecting it from harmful substances and pathogens in the blood circulation

▲Denali's transfer carrier platform (Image source: Denali's official website)

All patients in the trial had neuronal disease, except for one patient in cohort B who had non-neuronal disease MPS II

Long-term data from the trial demonstrated durability of CSF biomarker responses up to one year of dosing

References:

[1] Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial.

(Original abridged)

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Express breaks through the blood-brain barrier, Denali macromolecule delivery technology is expected to advance to Phase 2/3 clinical trials

03-08

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

Denali macromolecule delivery technology that breaks through the blood-brain barrier is expected to advance to phase 2/3 clinical trials

Related Articles

Express breaks through the blood-brain barrier, Denali macromolecule delivery technology is expected to advance to Phase 2/3 clinical trials